A decoy oligonucleotide to NF-κB delivered through inhalable particles prevents LPS-induced rat airway inflammation

American Journal of Respiratory Cell and Molecular Biology

Volumn 49, Issue 2, 2013, Pages 288-295

  De Stefano, Daniela ^a   Coletta, Ciro ^a   D'Emmanuele Di Villa Bianca, Roberta ^a   Falcone, Lucia ^a   D'Angelo, Ivana ^a   Ungaro, Francesca ^a   Quaglia, Fabiana ^a   Carnuccio, Rosa ^a   Sorrentino, Raffaella ^a  

^a UNIVERSITY OF NAPLES FEDERICO II   (Italy)

Author keywords

NF B oligonucleotide decoy; PLGA dry powders; Pseudomonas aeruginosa LPS; Pulmonary delivery; Rat lung inflammation

Indexed keywords

ANTIINFLAMMATORY AGENT; ANTISENSE OLIGODEOXYNUCLEOTIDE; BACTERIUM LIPOPOLYSACCHARIDE; DECOY OLIGODEOXYNUCLEOTIDE; DNA; DRUG CARRIER; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 6; INTERLEUKIN 8; LARGE POROUS PARTICLE; MESSENGER RNA; MUCIN 2; POLYGLACTIN; UNCLASSIFIED DRUG;

AERATION; AEROSOL; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTISENSE THERAPY; ARTICLE; CONTROLLED STUDY; DRUG DELIVERY SYSTEM; DRUG EFFECT; GENE EXPRESSION; LUNG HOMOGENATE; LUNG LAVAGE; MALE; NEUTROPHIL CHEMOTAXIS; NEUTROPHIL COUNT; NONHUMAN; PNEUMONIA; PROTEIN DNA BINDING; PROTEIN EXPRESSION; PSEUDOMONAS AERUGINOSA; RAT;

ANIMALS; DISEASE MODELS, ANIMAL; GENE EXPRESSION REGULATION; INTERLEUKIN-6; LACTIC ACID; LIPOPOLYSACCHARIDES; MALE; NEUTROPHIL INFILTRATION; NF-KAPPA B; OLIGODEOXYRIBONUCLEOTIDES; PNEUMONIA; POLYGLYCOLIC ACID; PSEUDOMONAS AERUGINOSA; RATS; RATS, WISTAR;

EID: 84883170046     PISSN: 10441549     EISSN: 15354989     Source Type: Journal    
DOI: 10.1165/rcmb.2012-0473OC     Document Type: Article

References (44)

1. World Health Organization. The global burden of disease: 2004 update. Geneva: World Health Organization; 2008.
2. Tam A, Wadsworth S, Dorscheid D, Man SF, Sin DD. The airway epithelium: more than just a structural barrier. Ther Adv Respir Dis 2011;5: 255-273.
3. Park GY, Christman JW. Nuclear factor kappa B is a promising therapeutic target in inflammatory lung disease. Curr Drug Targets 2006;7: 661-668.
4. Sadikot RT, HanW, Everhart MB, Zoia O, Peebles RS, Jansen ED, Yull FE, Christman JW, Blackwell TS. Selective I kappa B kinase expression in airway epithelium generates neutrophilic lung inflammation. J Immunol 2003;170: 1091-1098.
5. Carter AB, Monick MM, Hunninghake GW. Lipopolysaccharideinduced NF-kappaB activation and cytokine release in human alveolar macrophages is PKC-independent and TK- and PCPLC- dependent. Am J Respir Cell Mol Biol 1998;18: 384-391.
6. Beck-Schimmer B, Rosenberger DS, Neff SB, Jamnicki M, Suter D, Fuhrer T, Schwendener R, Booy C, Reyes L, Pasch T, et al. Pulmonary aspiration: new therapeutic approaches in the experimental model. Anesthesiology 2005;103: 556-566.
7. Edwards MR, Bartlett NW, Clarke D, Birrell M, Belvisi M, Johnston SL. Targeting the NF-kappaB pathway in asthma and chronic obstructive pulmonary disease. Pharmacol Ther 2009;121: 1-13.
8. Basbaum C, Lemjabbar H, Longphre M, Li D, Gensch E, McNamara N. Control of mucin transcription by diverse injury-induced signaling pathways. Am J Respir Crit Care Med 1999;160:S44-S48.
9. Hauber HP, Foley SC, Hamid Q. Mucin overproduction in chronic inflammatory lung disease. Can Respir J 2006;13: 327-335.
10. Thai P, Loukoianov A, Wachi S, Wu R. Regulation of airway mucin gene expression. Annu Rev Physiol 2008;70: 405-429.
11. Cabrini G, Bezzerri V, Mancini I, Nicolis E, Dechecchi MC, Tamanini A, Lampronti I, Piccagli L, Bianchi N, Borgatti M, et al. Targeting transcription factor activity as a strategy to inhibit pro-inflammatory genes involved in cystic fibrosis: decoy oligonucleotides and lowmolecular weight compounds. Curr Med Chem 2010;17: 4392-4404.
12. Sharma HW, Perez JR, Higgins-Sochaski K, Hsiao R, Narayanan R. Transcription factor decoy approach to decipher the role of NF-kappa B in oncogenesis. Anticancer Res 1996;16: 61-69.
13. Schmedtje JF Jr, Ji YS, Liu WL, DuBois RN, Runge MS. Hypoxia induces cyclooxygenase-2 via the NF-kappaB p65 transcription factor in human vascular endothelial cells. J Biol Chem 1997;272: 601-608.
14. Morishita R, Sugimoto T, Aoki M, Kida I, Tomita N, Moriguchi A, Maeda K, Sawa Y, Kaneda Y, Higaki J, et al. In vivo transfection of cis element "decoy" against nuclear factor-kappaB binding site prevents myocardial infarction. Nat Med 1997;3: 894-899.
15. Kawamura I, Morishita R, Tomita N, Lacey E, Aketa M, Tsujimoto S, Manda T, Tomoi M, Kida I, Higaki J, et al. Intratumoral injection of oligonucleotides to the NF kappa B binding site inhibits cachexia in a mouse tumor model. Gene Ther 1999;6: 91-97.
16. Egashira K, Suzuki J, Ito H, Aoki M, Isobe M, Morishita R. Longterm follow up of initial clinical cases with NF-kappaB decoy oligodeoxynucleotide transfection at the site of coronary stenting. J Gene Med 2008;10: 805-809.
17. Suzuki J, Tezuka D, Morishita R, Isobe M. An initial case of suppressed restenosis with nuclear factor-kappa B decoy transfection after percutaneous coronary intervention. J Gene Med 2009;11: 89-91.
18. Seguin RM, Ferrari N. Emerging oligonucleotide therapies for asthma and chronic obstructive pulmonary disease. Expert Opin Investig Drugs 2009;18: 1505-1517.
19. Lam JK, Liang W, Chan HK. Pulmonary delivery of therapeutic siRNA. Adv Drug Deliv Rev 2011;64: 1-15.
20. Ma Z, Zhang J, Alber S, Dileo J, Negishi Y, Stolz D, Watkins S, Huang L, Pitt B, Li S. Lipid-mediated delivery of oligonucleotide to pulmonary endothelium. Am J Respir Cell Mol Biol 2002;27: 151-159.
21. Li SD, Huang L. Targeted delivery of antisense oligodeoxynucleotide and small interference RNA into lung cancer cells. Mol Pharm 2006;3: 579-588.
22. Bezzerri V, Borgatti M, Nicolis E, Lampronti I, Dechecchi MC, Mancini I, Rizzotti P, Gambari R, Cabrini G. Transcription factor oligodeoxynucleotides to NF-kappaB inhibit transcription of IL-8 in bronchial cells. Am J Respir Cell Mol Biol 2008;39: 86-96.
23. Beisner J, Dong M, Taetz S, Piotrowska K, Kleideiter E, Friedel G, Schaefer U, Lehr CM, Klotz U, Murdter TE. Efficient telomerase inhibition in human non-small cell lung cancer cells by liposomal delivery of 29-O-methyl-RNA. J Pharm Sci 2009;98: 1765-1774.
24. Wijagkanalan W, Kawakami S, Higuchi Y, Yamashita F, Hashida M. Intratracheally instilled mannosylated cationic liposome/NFkappaB decoy complexes for effective prevention of LPS-induced lung inflammation. J Control Release 2011;149: 42-50.
25. Ungaro F, d'Angelo I, Miro A, La Rotonda MI, Quaglia F. Engineered PLGA nano- and micro-carriers for pulmonary delivery: challenges and promises. J Pharm Pharmacol 2012;64: 1217-1235.
26. Ungaro F, Giovino C, Coletta C, Sorrentino R, Miro A, Quaglia F. Engineering gas-foamed large porous particles for efficient local delivery of macromolecules to the lung. Eur J Pharm Sci 2010;41: 60-70.
27. De Stefano D, Ungaro F, Giovino C, Polimeno A, Quaglia F, Carnuccio R. Sustained inhibition of IL-6 and IL-8 expression by decoy ODN to NF-kappaB delivered through respirable large porous particles in LPS-stimulated cystic fibrosis bronchial cells. J Gene Med 2011;13: 200-208.
28. De Stefano D, De Rosa G, Maiuri MC, Ungaro F, Quaglia F, Iuvone T, Cinelli MP, La Rotonda MI, Carnuccio R. Oligonucleotide decoy to NF-kappaB slowly released from PLGA microspheres reduces chronic inflammation in rat. Pharmacol Res 2009;60: 33-40.
29. Yang Y, Tsifansky MD, Shin S, Lin Q, Yeo Y. Mannitol-guided delivery of ciprofloxacin in artificial cystic fibrosis mucus model. Biotechnol Bioeng 2011;108: 1441-1449.
30. Moss OR. Simulants of lung interstitial fluid. Health Phys 1979;36: 447-448.
31. de Lima WT, Sirois P, Jancar S. Immune-complex alveolitis in the rat: evidence for platelet activating factor and leukotrienes as mediators of the vascular lesions. Eur J Pharmacol 1992;213: 63-70.
32. Michel O, Nagy AM, Schroeven M, Duchateau J, Neve J, Fondu P, Sergysels R. Dose-response relationship to inhaled endotoxin in normal subjects. Am J Respir Crit Care Med 1997;156: 1157-1164.
33. O'Neill LA, Bowie AG. The family of five: TIR-domain-containing adaptors in Toll-like receptor signalling. Nat Rev Immunol 2007;7: 353-364.
34. Mitsuzawa H, Nishitani C, Hyakushima N, Shimizu T, Sano H,Matsushima N, Fukase K, Kuroki Y. Recombinant soluble forms of extracellular TLR4 domain and MD-2 inhibit lipopolysaccharide binding on cell surface and dampen lipopolysaccharide-induced pulmonary inflammation in mice. J Immunol 2006;177: 8133-8139.
35. Coldren CD, Nick JA, Poch KR, Woolum MD, Fouty BW, O'Brien JM, Gruber MP, Zamora MR, Svetkauskaite D, Richter DA, et al. Functional and genomic changes induced by alveolar transmigration in human neutrophils. Am J Physiol Lung Cell Mol Physiol 2006;291: L1267-L1276.
36. Li JD, Feng W, Gallup M, Kim JH, Gum J, Kim Y, Basbaum C. Activation of NF-kappaB via a Src-dependent Ras-MAPK- pp90RSK pathway is required for Pseudomonas aeruginosa-induced mucin overproduction in epithelial cells. Proc Natl Acad Sci USA 1998;95: 5718-5723.
37. Gambari R, BorgattiM, Bezzerri V, Nicolis E, Lampronti I, DechecchiMC, Mancini I, Tamanini A, Cabrini G. Decoy oligodeoxyribonucleotides and peptide nucleic acids-DNA chimeras targeting nuclear factor kappa-B: inhibition of IL-8 gene expression in cystic fibrosis cells infected with Pseudomonas aeruginosa. Biochem Pharmacol 2010;80: 1887-1894.
38. Isomura I, Morita A. Regulation of NF-kappaB signaling by decoy oligodeoxynucleotides. Microbiol Immunol 2006;50: 559-563.
39. Newman S, Anderson P, Byron P, Dalby R, Peart J. Respiratory drug delivery: essential theory and practice. Richmond, VA: RDD Online; 2009.
40. Coowanitwong I, Arya V, Kulvanich P, Hochhaus G. Slow release formulations of inhaled rifampin. AAPS J 2008;10: 342-348.
41. Ungaro F, De Stefano D, Giovino C, Masuccio A, Miro A, Sorrentino R, Carnuccio R, Quaglia F. PEI-engineered respirable particles delivering a decoy oligonucleotide to NF-kappaB: inhibiting MUC2 expression in LPS-stimulated airway epithelial cells. PLoS ONE 2012;7: e46457.
42. Jensen DK, Jensen LB, Koocheki S, Bengtson L, Cun D, Nielsen HM, Foged C. Design of an inhalable dry powder formulation of DOTAPmodified PLGA nanoparticles loaded with siRNA. J Control Release 2012;157: 141-148.
43. Hara K, Tsujimoto H, Tsukada Y, Huang CC, Kawashima Y, Tsutsumi M. Histological examination of PLGA nanospheres for intratracheal drug administration. Int J Pharm 2008;356: 267-273.
44. Yoo NY, Youn YS, Oh NM, Oh KT, Lee DK, Cha KH, Oh YT, Lee ES. Antioxidant encapsulated porous poly(lactide-co-glycolide) microparticles for developing long acting inhalation system. Colloids Surf B Biointerfaces 2011;88: 419-424.